Bicycle Therapeutics PLC
BCYC8.050USD
+0.060+0.75%
交易中 （美东）报价延迟15分钟
557.08M总市值
亏损市盈率 TTM
关于 Bicycle Therapeutics PLC 公司
Bicycle Therapeutics plc 是一家位于英国的临床阶段生物制药公司，正在开发一种新型药物，称为 Bicycle 分子，用于治疗现有疗法无法治疗的疾病。Bicycle 分子是完全合成的短肽，被小分子支架束缚，形成两个环，以稳定其结构几何形状。该公司正在公司赞助的临床试验中评估 BT8009，一种针对经过充分验证的肿瘤抗原 Nectin-4 的 Bicycle 毒素结合物 (BTC)；BT5528，一种针对历史上无法用药的靶点 EphA2 的 BTC；以及 BT7480，一种针对 Nectin-4 和激动 CD137 的 Bicycle 肿瘤靶向免疫细胞激动剂 (Bicycle TICA)。此外，该公司正在开发用于放射性药物的 Bicycle 放射性结合物 (BRC)，并通过各种合作伙伴关系，探索利用 Bicycle 技术开发肿瘤以外疾病的治疗方法。其候选产品还包括 BT1718 和 BT7455。
公司简介
公司代码BCYC
公司名称Bicycle Therapeutics PLC
上市日期May 23, 2019
CEODr. Kevin Lee, Ph.D.
员工数量305
证券类型Depository Receipt
年结日May 23
公司地址Blocks A & B, Portway Building
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United Kingdom
邮编CB21 6GS
电话11441223261503
网址https://www.bicycletherapeutics.com/
公司代码BCYC
上市日期May 23, 2019
CEODr. Kevin Lee, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
275.59K
-23.43%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
72.92K
+73.03%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
25.33K
-65.69%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
18.31K
+49.49%
Mr. Eric Westin, M.D.
Mr. Eric Westin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephen Sands
Mr. Stephen Sands
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Felix J. Baker, Ph.D.
Mr. Felix J. Baker, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Michael Hannay
Mr. Michael Hannay
Chief Product and Supply Chain Officer
Chief Product and Supply Chain Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
275.59K
-23.43%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
72.92K
+73.03%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
25.33K
-65.69%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
18.31K
+49.49%
Mr. Eric Westin, M.D.
Mr. Eric Westin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月14日 周一
更新时间: 7月14日 周一
持股股东
股东类型
持股股东
持股股东
占比
Baker Bros. Advisors LP
22.79%
Point72 Asset Management, L.P.
7.73%
Forbion Capital Partners
7.23%
Armistice Capital LLC
5.59%
Westfield Capital Management Company, L.P.
5.56%
Other
51.09%
持股股东
持股股东
占比
Baker Bros. Advisors LP
22.79%
Point72 Asset Management, L.P.
7.73%
Forbion Capital Partners
7.23%
Armistice Capital LLC
5.59%
Westfield Capital Management Company, L.P.
5.56%
Other
51.09%
股东类型
持股股东
占比
Hedge Fund
47.52%
Investment Advisor
17.21%
Investment Advisor/Hedge Fund
15.44%
Venture Capital
9.66%
Research Firm
3.69%
Individual Investor
1.60%
Pension Fund
0.20%
Family Office
0.06%
Other
4.61%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
261
45.57M
95.34%
-15.98M
2025Q1
263
46.04M
96.46%
-15.64M
2024Q4
263
44.84M
86.26%
-16.34M
2024Q3
260
44.49M
67.19%
-14.65M
2024Q2
252
44.12M
95.17%
-7.15M
2024Q1
268
34.84M
83.52%
-13.88M
2023Q4
272
34.95M
93.64%
-12.28M
2023Q3
272
41.70M
105.20%
-747.70K
2023Q2
255
34.13M
112.16%
-8.01M
2023Q1
245
32.53M
108.64%
-4.04M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Baker Bros. Advisors LP
10.89M
22.79%
-8.80K
-0.08%
Mar 31, 2025
Point72 Asset Management, L.P.
3.69M
7.73%
-862.83K
-18.94%
Mar 31, 2025
Forbion Capital Partners
3.45M
7.23%
--
--
Mar 31, 2025
Armistice Capital LLC
2.67M
5.59%
+476.00K
+21.68%
Mar 31, 2025
Westfield Capital Management Company, L.P.
2.66M
5.56%
+46.97K
+1.80%
Mar 31, 2025
Invus Public Equities Advisors, LLC
1.81M
3.8%
-26.65K
-1.45%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.54M
3.22%
-48.54K
-3.06%
Mar 31, 2025
Candriam Luxembourg S.A.
1.21M
2.53%
-20.80K
-1.69%
May 31, 2025
Long Focus Capital Management LLC
1.29M
2.71%
+750.66K
+138.22%
Mar 31, 2025
BNP Paribas Asset Management USA, Inc.
1.22M
2.55%
+64.04K
+5.54%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.72%
Harbor Health Care ETF
0.68%
Invesco NASDAQ Future Gen 200 ETF
0.38%
ALPS Medical Breakthroughs ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Health Innovation Active ETF
0.03%
iShares Biotechnology ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
Tema Oncology ETF
0%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.72%
Harbor Health Care ETF
占比0.68%
Invesco NASDAQ Future Gen 200 ETF
占比0.38%
ALPS Medical Breakthroughs ETF
占比0.22%
ProShares Ultra Nasdaq Biotechnology
占比0.03%
Invesco Nasdaq Biotechnology ETF
占比0.03%
iShares Health Innovation Active ETF
占比0.03%
iShares Biotechnology ETF
占比0.02%
SPDR S&P International Small Cap ETF
占比0.02%
Tema Oncology ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
